Validation of the Advisor HD Grid Mapping Catheter in Atrial Fibrillation Ablation
NCT ID: NCT04850508
Last Updated: 2022-11-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
20 participants
OBSERVATIONAL
2021-09-27
2022-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
High-Density (HD) Wave Mapping in Subjects With Atrial Fibrillation as a Predictor of Recurrence After a Single Ablation Procedure Using a PVI-Only Strategy
NCT03882021
Advisor HD Grid Observational Study
NCT03733392
STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation
NCT04428944
Mesh Ablator Versus Cryoballoon Pulmonary Vein Ablation of Symptomatic Paroxysmal Atrial Fibrillation
NCT01061931
Hybrid Therapy and Heart Team for Atrial Fibrillation
NCT03737929
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The main target in atrial fibrillation ablation is the isolation of the pulmonary veins (PVI). This is performed by point-by-point ablation with radiofrequency energy creating 2 circles, one around the left superior and inferior pulmonary vein and one around the right superior and inferior pulmonary vein. The current standard of mapping the pulmonary vein ostia during PVI ablation is a 20-pole circumferential catheter (CMC-20) which collects anatomical and electrical information by moving it in the left atrium and making contact with the atrial wall. Isolation of pulmonary veins is confirmed by other methods such as bidirectional block across the ablation lesions.
New technological developments have resulted in high-density mapping, such as the Advisor HD Grid mapping catheter by Abbott. This catheter has a total of 16 electrodes configured in a 4 by 4 matrix. With each electrical wavefront being decomposed to 2 orthogonal vectors, every direction of a local wavefront should be detected by these configurations and thus overcoming the bipolar blindness.
Research Question and Objectives:
The primary objective of this study is to demonstrate the superiority of the HD Grid catheter when compared to the CMC-20 catheter in atrial fibrillation ablation.
The primary endpoint is the mean number of gaps identified per patient, and their location identified by the HD Grid catheter after standard PVI procedure with the CMC-20 catheter.
Secondary endpoints are:
* A per vein analysis will be performed for the presence of gaps and for the mean number of gaps.
* A per pair of veins (left and right separately) analysis will be performed for the presence of gaps and for the mean number of gaps.
* Left atrial mapping time for both the CMC-20 and the HD Grid catheter
* Discrepancies in the prevalence of low voltage areas defined as a voltage \<0.50 mV between the CMC-20 and HD Grid catheter in sinus rhythm.
Design:
Prospective, single arm, single center, superiority study with comparison of standard 20-pole circular mapping catheter and the new HD Grid multipolar catheter.
A minimum of 20 evaluable subjects with drug refractory, symptomatic atrial fibrillation scheduled for first PVI ablation will be enrolled over a period of 12 months.
Data collection:
Demographic, clinical and AF-related information will be collected prior to the procedure. Procedure related information will be collected directly after the procedure. All data will be collected in RedCap.
Procedure:
First, a standard PVI procedure is performed. After completion of the ablation lesions, isolation of the pulmonary veins will be confirmed using the standard CMC-20 catheter. If isolation is confirmed, the CMC-20 catheter will be exchanged for the HD Grid catheter. Using the HD Grid catheter, a new map of the left atrium will be made using the high-density settings. Together with the left atrium, the pulmonary veins will be mapped again in search of electro-anatomical gaps. Gaps are defined as a local area from the ablation line reaching inwards the pulmonary vein which still shows activation or fractionated potentials in line with atrial activation whilst pacing remote in the left atrium. The prevalence and location of these gaps will be collected using the map. If gaps have been found, HD Grid guided additional ablation must be performed to achieve isolation in that vein.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mapping and ablation with the Advisor HD Grid catheter
After confirmation of isolation of the first pair of veins, the CMC-20 catheter will be exchanged for the HD Grid catheter. Using the HD Grid catheter, a new map of the left atrium will be made using the high-density settings. Together with the left atrium, the pulmonary veins will be mapped again in search of electro-anatomical gaps. Gaps are defined as a local area from the ablation line reaching inwards the pulmonary vein which still shows activation or fractionated potentials in line with atrial activation whilst pacing remote in the left atrium. The After mapping the first ablation side, the CMC-20 will be reinserted to repeat the protocol for the remaining pair of veins 30 minutes after ablation ended for that side.
If gaps have been found, HD Grid guided additional ablation must be performed to achieve isolation in that vein until isolation is reconfirmed.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients referred for a clinically indicated catheter ablation with a plan for PVI only.
3. 18-85 year of age at time of consent.
4. Able and willing to comply with all protocol requirements.
5. Signed patient Informed Consent (ICF).
Exclusion Criteria
2. Planned for left atrial ablation beyond PVI.
3. Uncontrolled heart Failure or NYHA Class III or IV heart failure.
4. Left ventricular ejection fraction \< 35 %
5. Left atrial size \> 55 mm diameter on echocardiogram.
6. Severe Pulmonary Hypertension
7. Reversible causes of AF (electrolyte imbalance, thyroid disease…)
8. Poor candidate for general anesthesia or deep sedation
9. Anticipated survival \< 1 year
10. MI or CABG within 3 months, severe valvular disease
11. Any documented thromboembolic event within 6 months.
12. Contraindication to systemic oral anticoagulation therapy.
13. Significant congenital anomaly or medical condition that may affect the integrity of study data.
14. Women who are pregnant or breastfeeding.
15. Active enrollment in another investigational study involving a drug or device.
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Calgary
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Vikas Kuriachan
Clinical Associate Professor (Cardiology/EP)
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Vikas P Kuriachan, MD
Role: PRINCIPAL_INVESTIGATOR
Libin Cardiovascular Institute of Alberta, University of Calgary
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Calgary
Calgary, Alberta, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Porterfield C, J Gora P, Wystrach A, Rossi P, Rillo M, A Sebag F, Giuggia M, Mantica M, Dorszewski A, Eldadah Z, Volpicelli M, Bottoni N, Jons C, T Hollis Z, Dekker L, Mathew S, Schmitt J, Nilsson K. Confirmation of Pulmonary Vein Isolation with High-Density Mapping: Comparison to Traditional Workflows. J Atr Fibrillation. 2020 Apr 30;12(6):2361. doi: 10.4022/jafib.2361. eCollection 2020 Apr-May.
Vandenberk B, Quinn FR, Barmby J, Wilton SB, Kuriachan V. High-density mapping improves detection of conduction gaps after pulmonary vein isolation ablation with a circular mapping catheter. J Interv Card Electrophysiol. 2023 Sep;66(6):1401-1410. doi: 10.1007/s10840-022-01434-3. Epub 2022 Dec 3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REB20-2140
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.